Spots Global Cancer Trial Database for leiomyosarcoma
Every month we try and update this database with for leiomyosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | NCT00815945 | Mesenchymal Tum... Carcinosarcoma Leiomyosarcoma | PegLiposomal Do... Carboplatin | 18 Years - | AGO Study Group | |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | NCT03114527 | Soft Tissue Sar... | Ribociclib Everolimus | 18 Years - | Fox Chase Cancer Center | |
| Localized Leiomyosarcoma Biomarker Protocol | NCT04925089 | Leiomyosarcoma | Blood and Tissu... | - | University of Michigan Rogel Cancer Center | |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | NCT04535271 | Leiomyosarcoma | Trabectedin | 18 Years - | Sarcoma Oncology Research Center, LLC | |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma | NCT00837148 | Sarcoma Synovial Sarcom... Leiomyosarcoma Malignant Perip... | Sorafenib and D... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| A Study of LY3435151 in Participants With Solid Tumors | NCT04099277 | Solid Tumor Triple-negative... Gastric Adenoca... Head and Neck S... Cervical Carcin... High Grade Sero... Hepatocellular ... Undifferentiate... Leiomyosarcoma | LY3435151 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| Exploring Clinical Trial Experiences of People With Leiomyosarcoma | NCT05548179 | Leiomyosarcoma | 18 Years - | Power Life Sciences Inc. | ||
| Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma | NCT02249702 | Leiomyosarcoma | gemcitabine + d... trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | NCT03016819 | Alveolar Soft P... Leiomyosarcoma Synovial Sarcom... Soft-Tissue Sar... | AL3818 Dacarbazine AL3818 or place... | 18 Years - | Advenchen Laboratories, LLC | |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | NCT06308419 | Leiomyosarcoma Soft-tissue Sar... | Gemcitabine Nab-Sirolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum | NCT02587169 | Retroperitoneal... Retroperitoneal... Chondrosarcoma | Nilotinib-adria... | 18 Years - 70 Years | Broto, Javier Martín, M.D. | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| A Study of Nivolumab in Selected Uterine Cancer Patients | NCT03241745 | Uterine Cancer Endometrial Car... Carcinosarcoma Leiomyosarcoma Undifferentiate... High Grade Endo... Clear Cell Carc... | Nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | NCT04535271 | Leiomyosarcoma | Trabectedin | 18 Years - | Sarcoma Oncology Research Center, LLC | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | NCT01692678 | Advanced or Met... | Trabectedin Dacarbazine | 15 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma | NCT01883518 | Sarcoma Neoplasms, Conn... | Autologous dend... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | NCT04811196 | Soft Tissue Sar... Malignant Perip... Leiomyosarcoma Endometrial Str... | Selinexor | 18 Years - | University Health Network, Toronto | |
| Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | NCT03851614 | Mismatch Repair... Pancreatic Aden... Leiomyosarcoma | Durvalumab Olaparib Cediranib | 18 Years - | University Health Network, Toronto | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | NCT00414076 | Leiomyosarcoma Uterine Neoplas... | Letrozole | 18 Years - | M.D. Anderson Cancer Center | |
| Vorinostat (SAHA) in Uterine Sarcoma | NCT03509207 | Leiomyosarcoma Endometrial Str... Carcinosarcomas... | Vorinostat Oral... | 18 Years - | Medical University of Graz | |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | NCT04811196 | Soft Tissue Sar... Malignant Perip... Leiomyosarcoma Endometrial Str... | Selinexor | 18 Years - | University Health Network, Toronto | |
| M6620 (VX-970) in Selected Solid Tumors | NCT03718091 | Solid Tumor Leiomyosarcoma Osteosarcoma | M6620 | 12 Years - | Massachusetts General Hospital | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Exploring Clinical Trial Experiences of People With Leiomyosarcoma | NCT05548179 | Leiomyosarcoma | 18 Years - | Power Life Sciences Inc. | ||
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | NCT06088290 | Leiomyosarcoma | Lurbinectedin Doxorubicin | 18 Years - | PharmaMar | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | NCT03899805 | Sarcoma Liposarcoma Leiomyosarcoma Undifferentiate... | Eribulin Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | NCT04906876 | Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma | Gemcitabine Docetaxel 9-ING-41 | 10 Years - | Brown University | |
| Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas | NCT04214457 | Leiomyoma Leiomyosarcoma | Biopsy and peri... | 18 Years - 75 Years | Igenomix | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | NCT05116800 | Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o... | Gemcitabine 9-ING-41 Docetaxel | 10 Years - | Brown University | |
| Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine | NCT01442662 | Leiomyosarcoma | pazopanib + gem... | 18 Years - | UNICANCER | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | NCT04420975 | Leiomyosarcoma Malignant Perip... Myxofibrosarcom... Pleomorphic Rha... Resectable Dedi... Resectable Soft... Resectable Undi... Soft Tissue Fib... Spindle Cell Sa... Stage I Retrope... Stage I Soft Ti... Stage IA Retrop... Stage IA Soft T... Stage IB Retrop... Stage IB Soft T... Stage II Retrop... Stage II Soft T... Stage III Retro... Stage III Soft ... Stage IIIA Retr... Stage IIIA Soft... Stage IIIB Retr... Stage IIIB Soft... Storiform-Pleom... Synovial Sarcom... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate... | Definitive Surg... Nanoplexed Poly... Nivolumab Radiation Thera... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| Localized Leiomyosarcoma Biomarker Protocol | NCT04925089 | Leiomyosarcoma | Blood and Tissu... | - | University of Michigan Rogel Cancer Center | |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | NCT04031677 | Retroperitoneal... Liposarcoma Leiomyosarcoma | Surgery Preoperative ch... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Bevacizumab and Radiation Therapy for Sarcomas | NCT00356031 | Soft Tissue Sar... Fibrous Histioc... Liposarcoma Leiomyosarcoma Fibrosarcoma Synovial Sarcom... | Bevacizumab Radiation Thera... Surgery | 18 Years - | Massachusetts General Hospital | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | NCT03773510 | Leiomyosarcoma Liposarcoma Synovial Sarcom... | Trabectedin dis... Trabectedin con... | 18 Years - | Italian Sarcoma Group | |
| A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | NCT03761095 | Leiomyosarcoma | Unesbulin Dacarbazine | 18 Years - | PTC Therapeutics | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma | NCT05116683 | Leiomyosarcoma Liposarcoma | ATX-101 | 18 Years - 99 Years | Columbia University | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | NCT03016819 | Alveolar Soft P... Leiomyosarcoma Synovial Sarcom... Soft-Tissue Sar... | AL3818 Dacarbazine AL3818 or place... | 18 Years - | Advenchen Laboratories, LLC | |
| Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors | NCT02940041 | Leiomyoma Leiomyosarcoma | Pre-surgical di... | 18 Years - | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| Metastatic Leiomyosarcoma Biomarker Protocol | NCT05653388 | Leiomyosarcoma | Plasma Collecti... | - | University of Michigan Rogel Cancer Center | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | NCT06088290 | Leiomyosarcoma | Lurbinectedin Doxorubicin | 18 Years - | PharmaMar | |
| Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma | NCT05080790 | Leiomyosarcoma | Dinutuximab Bet... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | NCT00887809 | Sarcoma Leiomyosarcoma Malignant Fibro... Histiocytoma Angiosarcoma | gemcitabine docetaxel bevacizumab | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | NCT03437070 | Leiomyosarcoma | Trabectedin Doxorubicin Olaratumab | 18 Years - | University of Miami | |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | NCT05712694 | Soft Tissue Sar... | ADI PEG20 Placebo | 18 Years - 99 Years | Polaris Group | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine | NCT01442662 | Leiomyosarcoma | pazopanib + gem... | 18 Years - | UNICANCER |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
